Positron emission tomography in nonsmall cell lung cancer

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 4, 2007, Pages 256-260

  Dooms, Christophe ^a   Vansteenkiste, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Early diagnosis; Positron emission tomography; Prognosis; Restaging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG UPTAKE; EARLY DIAGNOSIS; ECHOGRAPHY; ENDOSCOPY; FOLLOW UP; HUMAN; INVASIVE PROCEDURE; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINUM; MEDIASTINUM LYMPH NODE; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARD; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34249796675     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32816b5c50     Document Type: Review

References (24)

1. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006; 82:1016-1020.
2. max<2.5 compared with visual interpretation of PET in SPNs.
3. 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. J Nucl Med 2007; 48: 15-21.
4. 11C-acetate positron emission tomography imaging for lung adenocarcinoma 1 to 3cm in size with ground-glass opacity images on computed tomography. Ann Thorac Surg 2005; 80:2020-2025.
5. 18F-FDG PET versus nodule-enhancement CT. AJR Am J Roentgenol 2006; 187:1361-1367. Retrospective study on the potential role of CT and PET in the diagnostic strategy of lesions detected in lung cancer screening studies.
6. 18F]fluorodeoxyglucose positron emission tomography staging of nonsmall cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006; 24:1800-1806. Prospective randomized study showing that staging of NSCLC based on a baseline PET does not result in a loss of accuracy.
7. 18F]fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable nonsmall cell lung cancer. J Clin Oncol 2005; 23:8348-8356.
8. De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007; 17:467-473.
9. Bryant AS, Cerfolio RJ, Klemm KM, Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with nonsmall cell lung cancer. Ann Thorac Surg 2006; 82:417-423.
10. Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006; 130:710-718.
11. De Leyn P, Stroobants S, DeWever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy proven stage IIIA-N2 nonsmall cell lung cancer: a Leuven Lung Cancer Group study. J Clin Oncol 2006; 24:3333-3339. Prospective comparator study with integrated PET/CT versus redo mediastinoscopy for restaging after induction chemotherapy for stage IIIA-N2 NSCLC.
12. 18F-fluoro-2-deoxy-Dglucose-positron emission tomography/computed tomography in nonsmall cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12:97-106.
13. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2(stage IIIa) nonsmall cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006; 131:1229-1235. Large prospective study showing that repeat PET after neoadjuvant chemoradiotherapy in stage IIIA-N2 NSCLC can accurately predict complete pathological response.
14. Ohtsuka T, Nomori H, Ebihara A, et al. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg 2006; 12:89-94.
15. Cerfolio RJ, Ojha B, Bryant AS, et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004; 78:1017-1023.
16. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Prognostic importance of the standardized uptake value on FDG-PET-scan in nonsmall cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999; 17:3201-3206.
17. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83:918-924.
18. 18F- fluorodeoxyglucose uptake by positron emission tomography predicts outcome of nonsmall cell lung cancer. J Clin Oncol 2005; 23:1136-1143.
19. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a nonsmall cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005; 130:151-159.
20. Kramer H, Post WJ, Pruim J, Groen HJ. The prognostic value of positron emission tomography in non small cell lung cancer: analysis of 266 cases. Lung Cancer 2006; 52:213-217. A large study showing that PET TNM stage is the most significant prognostic factor for survival.
21. 18F-FDG-PET on outcome of patients with stage III nonsmall cell lung cancer: PET identifies potential survivors. Eur J Nucl Med Mol Imaging 2007; 34:54-59.
22. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 nonsmall cell lung cancer: a prospective pilot study. Ann Oncol 1998; 9:1193-1198.
23. 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III nonsmall cell lung cancer. Lung Cancer 2007; 55:165-171. First report showing the impact on long-term outcome of repeat PET on the primary tumor after neoadjuvant therapy in stage IIIA-N2 NSCLC.
24. Hellwig D, Groschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 2006; 33:13-21. Prospective study that confirms the accuracy of PET in detection of lung cancer recurrence and in patient selection for surgical retreatment.